An award-winning software developed by our team from PwC Switzerland combining artificial intelligence (AI) and analytics technology, medical insight and human-centred design to make the treatment of multiple sclerosis more effective and cost-efficient.
In a project with NeuroTransData (NTD), a network of neurologists and psychiatrists in the area of multiple sclerosis (MS), we co-designed the first predictive healthcare solution for MS patients. PHREND offers both, physicians and patients an effective comparison of different MS therapies.
Powered by an algorithm that comprises the data of different forms of therapy of 25’000 patients over the course of more than ten years, PHREND gives patients and doctors a second opinion on what drugs and therapies are likely to be most effective and a match with a patient’s personal characteristics and needs.
Individualised forms of treatment for patients with neurological disorders
PHREND is a software developed to improve care for people with MS, a neurodegenerative disorder that mostly affects young people. With no cure found so far, therapy focuses on delaying the progress of the disease. Until now, choosing the right form of treatment for individual patients from the many options available has been largely a matter of trial and error, which is costing the healthcare system staggering amounts of money and ultimately increases the suffering of people with MS.
“PHREND enables me to work more efficiently and make better decisions. The tool gives me an added degree of certainty and is a solid basis to justify the choice of therapy in front of health insurers.”
"(Platzhalter!) Personalised healthcare solutions that use AI algorithms and are based on the authentic data of thousands of patients make choosing a suitable treatment for physicians both safer and more transparent.”
Easy to use and understand. For patients and physicians.
We used a human-centred design approach to develop the personalised healthcare solution PHREND for a network of neurological specialists in collaboration with patients, their doctors and leading universities. The tool employs an algorithm driven by artificial intelligence (AI) to generate predictions of treatment efficacy within seconds, based on the ten most important patient characteristics that are clinically relevant to MS. Extensive user testing over ten design iterations has made the application easy to use and understand, both for patients and their physicians.
The award-winning software PHREND is the world’s first application able to provide personalised predictions of the efficacy of treatment options for people suffering from multiple sclerosis. It’s a predictive analytics tool embedded in a patient-centred, database-assisted ecosystem that connects different disciplines and resources to provide patients and their physicians with a data-based second opinion in the treatment process. Thanks to its accurate predictions and straightforward integration in the existing hospital environment, the personalised healthcare solution enjoys wide acceptance within the medical community.
Get in touch with our health analytics experts
Do you want to find out more about the targeted and individualised clinical decision-making? Share your email address and we will be in touch.
https://pages.pwc.ch/core-contact-page?form_id=7014I0000006qZkQAI&lang=en&embed=true
Contact us
